HebeCell Corp., a Natick research company focused on therapies for cancer and autoimmune disease, announced on Tuesday it has closed a $53-million Series A financing for an off-the-shelf stem cell product.
The investment was led by Jacobio Pharmaceuticals, headquartered in China, who will collaborate with HebeCell to develop the (PSC)-CAR-NK therapy, according to the press release.
The treatment is a form of natural killer cell, which helps activate the immune system against abnormal cells. NK cells are used to treat cancer, viral infection, and autoimmune diseases.
HebeCell was founded in 2016 and is focused on making NK cell therapeutics affordable and available to clinics worldwide.
